Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > AMRI > Summary

Albany Molecular Research Inc.
(AMRI)

8.46USD   Up0.03 (0.36%)   
At 2:30AM IST
 Albany Molecular Research Inc. (NasdaqNM:AMRI) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Last Trade: 8.46USD
Trade Time:2:30AM IST
Change:Up0.03 (0.36%)
Prev Close:8.43
Open:8.70
Bid:7.96 x 200
Ask:8.96 x 200
1y Target Est:8.00
Day's Range:8.43 - 9.42
52wk Range:7.31 - 11.31
Volume:214,907
Avg Vol (3m):79,355.6
Market Cap:267.70M
P/E (ttm):46.74
EPS (ttm):0.18
Div & Yield:N/A (N/A%)
Add AMRI to Portfolio   Download Data

HEADLINES

 
•AMRI reports $19M net loss in 4Q - bizjournals.com  - Mon, Feb 8
•ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements - EDGAR Online  - Mon, Feb 8
•AMRI Announces Fourth Quarter 2009 Results - Business Wire  - Mon, Feb 8
•AMRI CFO to Present at UBS 20th Annual Global Healthcare Services Conference - Business Wire  - Tue, Feb 2
•AMRI to Announce Fourth Quarter Results - Business Wire  - Mon, Feb 1
•Research And Development Expenditures In Diagnostic And Lab Equipment Sector Raises Capital Requirements: Will Acquisitions By Larger Health Care Companies Be The Result? - Wall Street Transcript  - Thu, Jan 28
•AMRI CFO to Present at Jefferies 2010 Global Healthcare Services Conference - Business Wire  - Tue, Jan 19
•AMRI Receives SafeBridge® Potent Compound Safety Certification - Business Wire  - Tue, Jan 19
•AMRI CEO to Present at 28th Annual J.P. Morgan Healthcare Conference - Business Wire  - Thu, Jan 7
•Bruno name stays put in Capital Region - bizjournals.com  - Thu, Dec 10
» More Headlines for AMRI...

ANALYST

 
EPS Est (next year) (Dec-09) :0.03
EPS Est (in 2 years) (Dec-10) :0.17
Avg Rec (current)*:3.0
PEG Ratio:31.27
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
Albany Molecular Research, Inc. provides contract services to various pharmaceutical and biotechnology companies primarily in the United States and Europe.

» Full Company Profile